Santhera's Lack of FDA Support is not a Read Through for Sarepta Therapeutics (SRPT) - Oppenheimer
July 15, 2016 10:58 AM
Oppenheimer analyst, Michele Gilson reiterated her Outperform rating on Sarepta Therapeutics (NASDAQ: SRPT) after Santhera announced today that the FDA ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
